Bill > HR843

This bill amends the Federal Food, Drug, and Cosmetic Act to expedite the approval process for generic drugs by allowing them to be approved even when certain safety information is temporarily omitted from their labeling. Specifically, the bill permits drug applications to be approved under subsections (b)(2) or (j) of Section 505 even if some safety information is not included, provided that the omitted information is protected by exclusivity periods, patent protections, or other regulatory mechanisms. The Secretary of Health and Human Services would still be required to ensure that any critical safety information is included in the drug's labeling to guarantee safe use. The bill does not impact the existing exclusivity periods or overall eligibility for drug approval, but rather creates a pathway for faster generic drug approvals by allowing temporary omissions of safety information that is already protected elsewhere. This legislation aims to streamline the generic drug approval process while maintaining important safety standards, potentially making more affordable medication options available to consumers more quickly.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/843/all-info